

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

MBHB00-327-A

Serial No.

09/835,603

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Sarah S. Bacus et al.

Filing Date:

04/16/2001

Group:

1632

 NOV 07 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
|------------------|----|-----------------|------------|-------|-------|----------|----------------------------|
| KSI | 1. | 2001/044124 | 11/22/2001 | Bacus | | | |
| KSI | 2. | 2002/037541 | 3/28/2002 | Obata | | | |

FOREIGN PATENT DOCUMENTS

| | | Document Number | Date | Country | Class | Subclass | Translation | |
|-----|----|-----------------|------------|---------|-------|----------|-------------------------------------|--------------------------|
| | | | | | | | Yes | No |
| KSI | 3. | WO 01/79557 | 10/25/2001 | PCT | | | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| KSI | 4. | WO 01/79855 | 10/25/2001 | PCT | | | <input checked="" type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


| | | |
|-----|----|---|
| KSI | 5. | Arteaga et al., "p185 ^{c-erbB-2} Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair," Cancer Res., 54:3758-3765, 1994. |
| KSI | 6. | Bacus et al., "AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival," Oncogene, England, Vol. 21, No.22:3532-3540, May 16, 2002. |
| KSI | 7. | Bacus et al., "Akt2 upregulation in HER-2/neu-overexpressing breast cancers: Implications to their clinical and biological behavior," Proceedings of the American Association For Cancer Research Annual, Vol. 42:243, March 2001. |
| KSI | 8. | Bacus et al., "Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells," Oncogene, 12:2535-2547, 1996. |

EXAMINER

DATE CONSIDERED

9/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.




RECEIVED
NOV 07 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

| | | |
|---|-----|--|
| ✓ | 9. | Bacus et al., "Potential Use of Image Analysis for the Evaluation of Cellular Predicting Factors for Therapeutic Response in Breast Cancers," Anal. Quant. Cytol. Histol., 19:316-328, 1997. |
| ✓ | 10. | Bacus et al., "Type 1 Receptor Tyrosine Kinases Are Differentially Phosphorylated in Mammary Carcinoma and Differentially Associated with Steroid Receptors," American Journal of Pathology, 148(2):549-558, 1996. |
| ✓ | 11. | Cantley and Neel, "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway," Proc. Natl. Acad. Sci. U.S.A., 96:4240-45, 1999. |
| ✓ | 12. | Cobleigh et al., "Mutational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease," J. Clin. Oncol., 17:2639-2648, 1999. |
| ✓ | 13. | Datta et al., "Cellular survival: a play in three Akts," Genes and Dev., 13:2905-27, 1999. |
| ✓ | 14. | Hancock et al., "A Monoclonal Antidoby against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines," Cancer Res., 51:4575-4580, 1991. |
| ✓ | 15. | Li et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer," Science 275:1943-47, 1997. |
| ✓ | 16. | Liaw et al., "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome," Nat. Genet., 16:64-67, 1997. |
| ✓ | 17. | Liu et al., "Heregulin Regulation of Akt/Protein Kinase B in Breast Cancer Cells," Biochem. Biophys. Res. Commun., 261:897-903, 1999. |
| ✓ | 18. | National Institue of Health Consensus Development Conference: Steroid Receptors in Breast Cancer, 1979, Bethesda, MD. |
| ✓ | 19. | Nelen et al., "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease," Hum. Mol. Genet., 6:1383-87, 1997. |
| ✓ | 20. | Peles et al., "Cell-type specific Interaction of Neu differentiation factor (NDF/hergulin) with Neu/HER-2 suggests complex ligand - receptor relationships," EMBO J., 12(3):961-971, 1993. |
| ✓ | 21. | Peles et al., "Neu and its Ligands: From an Oncogene to Neural Factors," BioEssays, 15(12):815-924, 1993. |
| ✓ | 22. | Pettmann and Henderson, "Neuronal Cell Death," Neuron, 20:633-47, 1998. |
| ✓ | 23. | Shak, "Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal Antibody Clinical Program in HER2-Overexpressing Metastatic Breast Cancer," Semin. Oncol., 26:71-77, 1999. |
| ✓ | 24. | Sliwkowski et al., "Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin)," Semin. Oncol., 26:60-70, 1999. |
| ✓ | 25. | Yang et al., "Bad, a Heterodimeric Partner for Bcl-x _L and Bcl-2, Displaces Bax and Promotes Cell Death," Cell, 80:285-91, 1995. |
| ✓ | 26. | Zundel and Giaccia, "Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress," Genes Dev., 12:941-46, 1998. |
| ✓ | 27. | Daly et al., "Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells," Cancer Res., 57(17):3804-11, 1997. |

| | |
|---|----------------------------|
| EXAMINER  | DATE CONSIDERED 9/25/03 |
|---|----------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.